PD-L1 expression in Epstein-Barr virus-infected gastric cancers.

Authors

null

Sarah Derks

dana-farber cancer institute, Boston, MA

Sarah Derks , Xiaoyun Liao , Xinsen Xu , M. Constanza Camargo , Anna M Chiaravalli , Enrico Solcia , Tania Fleitas , Gordon J. Freeman , Scott J. Rodig , Charles S. Rabkin , Adam Joel Bass

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4052)

DOI

10.1200/JCO.2016.34.15_suppl.4052

Abstract #

4052

Poster Bd #

44

Abstract Disclosures

Similar Posters

Poster

2016 ASCO Annual Meeting

Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues.

Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues.

First Author: Robbie G. Majzner

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Microsatellite instability (MSI) in patients with gastric cancer (GC) and correlation with PD-L1 expression.

Microsatellite instability (MSI) in patients with gastric cancer (GC) and correlation with PD-L1 expression.

First Author: Henian Sun

Poster

2021 ASCO Annual Meeting

Differentiated activity profile for the PD-1 inhibitor balstilimab.

Differentiated activity profile for the PD-1 inhibitor balstilimab.

First Author: Cailin Joyce

Poster

2019 Genitourinary Cancers Symposium

A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).

A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).

First Author: David Johnson Einstein